Featured Research

from universities, journals, and other organizations

Angiotensin receptor blockers associated with lower risk of Alzheimer's disease

Date:
January 14, 2010
Source:
Boston University Medical Center
Summary:
Researchers have found that angiotensin receptor blockers -- a particular class of anti-hypertensive medicines -- are associated with a striking decrease in the occurrence and progression of dementia.

Researchers from Boston University School of Medicine (BUSM) have found that angiotensin receptor blockers (ARBs) -- a particular class of anti-hypertensive medicines -- are associated with a striking decrease in the occurrence and progression of dementia. These findings appear in the January issue of the British Medical Journal.

Using data from the Decision Support System Database of the U.S. Department of Health System Veterans Affairs (with information on more than 5 million people), the BUSM researchers looked at records from patients who used ARBs, and compared them with subjects who had a similar health status, but were taking different medications. They found patients taking ARBs had up to a 50 percent lower chance of getting Alzheimer's disease or dementia. Patients taking two forms of medications targeting the angiotensin system, ARBs and Angiotensin Converting Enzyme (ACE) inhibitors, had a 55 percent lower risk of dementia.

The researchers also examined patients who were already suffering from Alzheimer's disease or dementia, and found those subjects had up to a 67 percent lower chance of being admitted to nursing homes or dying if they were taking both ARBs and ACE inhibitors. Patients who appeared to benefit particularly well from use of ARBs were those who had experienced strokes before or during the course of their illness.

According to the BUSM researchers these results suggest that ARBs might protect against developing Alzheimer's disease and dementia. "For those who already have dementia, use of ARBs might delay deterioration of brain function and help keep patients out of nursing homes," said senior author Benjamin Wolozin, MD, PhD, a professor of pharmacology at BUSM. "The study is particularly interesting because we compared the effects of ARBs to other medications used for treating blood pressure or cardiovascular disease. This suggests that ARBs are more effective than other blood pressure and cardiovascular medications for preventing Alzheimer's disease or dementia," he added.

Although the researchers are unsure why ARBs might be so beneficial, they believe one possibility suggested by prior studies on animal models is that ARBs help prevent nerve cell injury from blood vessel damage or help promote nerve cell recovery after blood vessel damage. The authors also speculate that ARBs might help protect the blood vessels in the brain against damage related to cardiovascular disease. Damage to blood vessels is thought to reduce brain capacity and promote dementia, so reducing this damage might prevent the occurrence or progression of dementia.

Funding for this study was provided by the Retirement Research Foundation and from the Casten Foundation.


Story Source:

The above story is based on materials provided by Boston University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Boston University Medical Center. "Angiotensin receptor blockers associated with lower risk of Alzheimer's disease." ScienceDaily. ScienceDaily, 14 January 2010. <www.sciencedaily.com/releases/2010/01/100112201345.htm>.
Boston University Medical Center. (2010, January 14). Angiotensin receptor blockers associated with lower risk of Alzheimer's disease. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2010/01/100112201345.htm
Boston University Medical Center. "Angiotensin receptor blockers associated with lower risk of Alzheimer's disease." ScienceDaily. www.sciencedaily.com/releases/2010/01/100112201345.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins